Peruvian economic watchdog INDECOPI has issued fines on five major drug store chains, having determined their involvement in a price-fixing scheme affecting 36 major medications, violating competition legislation and adversely affecting consumers.
Charges were presented against the Arcangel (Albis SA), Fasa (Farmacias Peruanas SA), Inkafarma (Eckerd Perú SA), Mifarma (Mifarma SA) and Felicidad (Nortfarma SAC) drug store chains, with fines totalling approximately $2,641,992 USD for their involvement in actions classed as ‘anticompetitive’ by Peru’s antitrust legislation.
As well as the economic sanctions mentioned, INDECOPI’s Commission for the Defense of Free Competition (CLC) has ordered the companies to design and implement a three-year program to avoid any relapse into uncompetitive behavior, including special training for sales personnel.
Full Content: Kaos en la Red
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Big Tech Braces for Potential Changes Under a Second Trump Presidency
Nov 6, 2024 by
CPI
Trump’s Potential Shift in US Antitrust Policy Raises Questions for Big Tech and Mergers
Nov 6, 2024 by
CPI
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI